Aurobindo Pharma
Aurobindo Pharma Limited, commonly known as Aurobindo Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Hyderabad, India. Founded in 1986, the company has established a strong presence in over 150 countries, with significant operations across North America, Europe, and Asia. Specialising in the manufacture of generic pharmaceuticals, Aurobindo Pharma offers a diverse portfolio that includes formulations, active pharmaceutical ingredients (APIs), and biosimilars. The company is recognised for its commitment to quality and innovation, which has propelled it to a leading position in the market. With numerous regulatory approvals and a robust pipeline of products, Aurobindo Pharma continues to achieve notable milestones, solidifying its reputation as a trusted provider of affordable healthcare solutions worldwide.
DitchCarbon Score
How does Aurobindo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aurobindo Pharma's score of 47 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aurobindo Pharma's reported carbon emissions
In 2024, Aurobindo Pharma reported total carbon emissions of approximately 493,168,000 kg CO2e across all scopes, with specific emissions of about 11,797,700 kg CO2e for Scope 1 and about 15,717,600 kg CO2e for Scope 2. The combined emissions for Scope 1 and Scope 2 amounted to approximately 27,515,400 kg CO2e. In 2023, the company recorded total emissions of about 5,346,000 kg CO2e for Scope 3, alongside Scope 1 emissions of approximately 13,036,600 kg CO2e and Scope 2 emissions of about 18,353,100 kg CO2e, leading to a total of around 31,389,700 kg CO2e for Scope 1 and 2. Aurobindo Pharma has set ambitious climate commitments, aiming for a 12.5% reduction in its carbon footprint for both Scope 1 and Scope 2 emissions by 2025, in line with the Science Based Targets initiative, which aligns with a well below 2°C scenario. This target reflects the company's commitment to reducing its environmental impact and contributing to global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 409,572,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 523,611,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 0,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aurobindo Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
